THE ROLE OF METABOLIC SYNDROME IN THE DEVELOPMENT OF ATHEROSCLEROSIS

Qambarov Azizbek Oybek oglu

RSHTYoIM, Navoi branch, clinical Ordinator

Turniyazov Azamat Askarovich

Head of the Emergency Cardiology Department of the Navoi

Branch of the RSHTYoIM Hospital, a doctor of the highest category

ABSTRACT

Metabolic syndrome represents a cluster of interconnected metabolic abnormalities that collectively substantially elevate the risk of atherosclerotic cardiovascular disease. This comprehensive review examines the pathophysiological mechanisms through which metabolic syndrome contributes to the development and progression of atherosclerosis. The syndrome, characterized by central obesity, insulin resistance, dyslipidemia, and hypertension, creates a pro-inflammatory and pro-thrombotic environment that accelerates endothelial dysfunction and plaque formation. Current evidence demonstrates that each component of metabolic syndrome independently contributes to vascular damage, while their combination produces synergistic deleterious effects. The prevalence of metabolic syndrome continues to increase globally, reaching approximately twenty five percent of the world adult population, creating an urgent public health challenge . This review synthesizes current understanding of the molecular pathways linking metabolic syndrome to atherosclerosis, including insulin resistance signaling disruption, adipokine imbalance, endoplasmic reticulum stress, oxidative stress, and chronic low-grade inflammation. Additionally, this paper examines clinical evidence from epidemiological studies and intervention trials, discusses diagnostic challenges, and explores therapeutic strategies targeting both individual components and shared underlying mechanisms. Understanding these complex interactions is essential for developing effective prevention and treatment approaches for the growing population at risk.

Key words:metabolic syndrome, atherosclerosis, insulin resistance, cardiovascular disease, endothelial dysfunction, inflammation, dyslipidemia, central obesity, oxidative stress

INTRODUCTION

Atherosclerotic cardiovascular disease remains the leading cause of mortality worldwide, accounting for millions of deaths annually despite significant advances in prevention and treatment strategies. Among the numerous risk factors contributing to atherosclerosis, metabolic syndrome has emerged as a particularly important and prevalent condition that substantially accelerates vascular pathology. Metabolic syndrome, initially described as syndrome X by Reaven in 1988, encompasses a constellation of interrelated metabolic disturbances including central obesity, insulin resistance, dyslipidemia characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol, and hypertension .

The clinical significance of metabolic syndrome lies not merely in the presence of individual risk factors but in their synergistic interaction, which amplifies cardiovascular risk beyond the sum of its components. Individuals with metabolic syndrome face approximately twice the risk of developing cardiovascular disease compared to those without the syndrome, and this elevated risk manifests across diverse populations and age groups . The pathophysiological links between

metabolic syndrome and atherosclerosis are complex and multifaceted, involving disturbances in glucose and lipid metabolism, alterations in adipose tissue function, activation of inflammatory pathways, and oxidative stress. Current global estimates indicate that approximately twenty five percent of the world adult population meets criteria for metabolic syndrome, with prevalence reaching as high as thirty nine point eight percent in some developed nations . Particularly concerning is the increasing prevalence among younger individuals and in developing countries adopting Western dietary patterns and sedentary lifestyles. The economic burden associated with metabolic syndrome and its cardiovascular complications is substantial, encompassing direct healthcare costs and indirect costs from lost productivity. Despite extensive research, the precise mechanisms by which metabolic syndrome promotes atherosclerosis continue to be elucidated. Emerging evidence highlights the critical role of adipose tissue dysfunction, ectopic lipid accumulation, and inflammatory signaling pathways that integrate metabolic and immune responses. Understanding these mechanisms is essential for identifying therapeutic targets and developing effective intervention strategies. This review aims to provide a comprehensive examination of the role of metabolic syndrome in atherosclerosis development, integrating current knowledge from molecular studies, clinical investigations, and population-based research.

LITERATURE REVIEW

Historical Evolution and Diagnostic Criteria **-** The concept of metabolic syndrome has evolved considerably since its initial description. The recognition that cardiovascular risk factors tend to cluster dates back to the early twentieth century, but the formal conceptualization emerged with Reaven's 1988 description of syndrome X, which emphasized insulin resistance as the central pathogenic mechanism . Subsequent decades witnessed the development of multiple diagnostic criteria by various organizations, creating challenges for clinical practice and epidemiological research. The World Health Organization proposed the first standardized definition in 1998, requiring evidence of insulin resistance or diabetes mellitus plus at least two additional components including obesity, dyslipidemia, hypertension, or microalbuminuria . The European Group for the Study of Insulin Resistance subsequently modified these criteria, emphasizing hyperinsulinemia as the essential feature. The National Cholesterol Education Program Adult Treatment Panel III definition, published in 2001, gained widespread acceptance due to its clinical practicality, requiring any three of five equally weighted components.

Recognizing the need for harmonization, major organizations including the International Diabetes Federation, American Heart Association, and National Heart Lung and Blood Institute jointly issued harmonized criteria in 2009 . These unified criteria establish the diagnosis when three or more of five components are present: elevated waist circumference with population and country specific cutoffs, elevated triglycerides defined as one hundred fifty milligrams per deciliter or greater, reduced high-density lipoprotein cholesterol below forty milligrams per deciliter in men or fifty milligrams per deciliter in women, elevated blood pressure defined as systolic one hundred thirty millimeters of mercury or greater or diastolic eighty five millimeters of mercury or greater, and elevated fasting glucose defined as one hundred milligrams per deciliter or greater .

Epidemiology and Global Burden - The global prevalence of metabolic syndrome varies considerably across populations, reflecting differences in genetic susceptibility, dietary patterns, physical activity levels, and demographic characteristics. A comprehensive analysis of global data estimates the overall prevalence at approximately twenty five percent, with higher rates in developed nations and urban populations of developing countries . The United States National Health and Nutrition Examination Survey data from 2011 to 2018 revealed that thirty nine point eight percent of United States adults meet metabolic syndrome criteria, with prevalence

increasing dramatically with age from twenty two point two percent among those aged twenty to thirty nine years to fifty six point four percent among those aged sixty years and above . Significant ethnic and geographic variations exist. Hispanic Americans demonstrate the highest prevalence among United States ethnic groups, while Asian populations generally exhibit lower body mass index thresholds for metabolic abnormalities . In China, estimated prevalence reaches twenty four point two percent, with older individuals and women showing increased odds of having the syndrome. African populations show approximately thirty two point four percent prevalence, with concerning increases attributed to lifestyle changes and human immunodeficiency virus antiretroviral therapy in affected populations .

The public health impact extends beyond prevalence statistics. Metabolic syndrome significantly increases risk for cardiovascular disease, type two diabetes mellitus, and all cause mortality. Longitudinal studies demonstrate that individuals with metabolic syndrome have approximately two fold increased risk for cardiovascular events compared to those without the syndrome . The population attributable risk is substantial, meaning that a considerable proportion of cardiovascular disease cases could potentially be prevented through effective metabolic syndrome management.

Molecular Mechanisms Linking Metabolic Syndrome to Atherosclerosis

Insulin Resistance and Vascular Dysfunction - Insulin resistance represents a central pathogenic feature of metabolic syndrome with direct and indirect effects on vascular health. Under physiological conditions, insulin exerts vasodilatory effects through stimulation of endothelial nitric oxide production, promoting vascular health and normal blood flow. In insulin resistant states, this protective pathway becomes selectively impaired while other insulin signaling pathways remain active or become exaggerated . The molecular basis of this selective insulin resistance involves complex signaling networks. Insulin receptor activation normally stimulates two major downstream pathways: the phosphatidylinositol three kinase pathway leading to nitric oxide production and metabolic effects, and the mitogen activated protein kinase pathway promoting cell growth and migration. In metabolic syndrome, the phosphatidylinositol three kinase pathway becomes desensitized while the mitogen activated protein kinase pathway remains responsive, creating an imbalance favoring pro-atherogenic processes . This results in impaired vasodilation, increased endothelial adhesion molecule expression, and enhanced vascular smooth muscle cell proliferation. Chronic hyperinsulinemia, resulting from compensatory pancreatic insulin secretion, further exacerbates vascular pathology. Elevated insulin levels directly stimulate hepatic very low density lipoprotein production, promote vascular smooth muscle cell proliferation, and enhance endothelin one mediated vasoconstriction. Additionally, insulin resistance in adipose tissue impairs the suppression of lipolysis, leading to increased circulating free fatty acids that perpetuate insulin resistance and directly damage vascular endothelium .

Adipose Tissue Dysfunction and Adipokine Imbalance - The recognition of adipose tissue as an active endocrine organ rather than passive energy storage has revolutionized understanding of metabolic syndrome pathophysiology. Adipose tissue secretes numerous bioactive molecules termed adipokines that influence insulin sensitivity, inflammation, and vascular function. In obesity, particularly visceral obesity characteristic of metabolic syndrome, adipose tissue undergoes significant functional alterations.

Expanding adipose tissue experiences relative hypoxia, leading to adipocyte stress and dysfunction. Macrophages infiltrate adipose tissue, constituting up to forty percent of cells in obese adipose tissue compared to ten percent in lean individuals . These macrophages adopt a

pro-inflammatory phenotype and contribute to local and systemic inflammation. Adipokine secretion becomes profoundly altered, with decreased production of protective adipokines such as adiponectin and increased production of deleterious adipokines including leptin, resistin, and pro-inflammatory cytokines. Adiponectin, which is consistently reduced in metabolic syndrome, normally exerts anti-atherogenic effects through multiple mechanisms including enhancement of endothelial nitric oxide production, suppression of vascular adhesion molecule expression, inhibition of macrophage foam cell formation, and promotion of vascular smooth muscle cell phenotypic stability. Conversely, elevated leptin contributes to hypertension through sympathetic nervous system activation, promotes platelet aggregation, and stimulates vascular inflammation . This adipokine imbalance creates a vascular environment conducive to atherosclerosis initiation and progression.

Dyslipidemia and Lipoprotein Modification - The characteristic dyslipidemia of metabolic syndrome, featuring elevated triglycerides, reduced high-density lipoprotein cholesterol, and accumulation of small dense low-density lipoprotein particles, directly promotes atherogenesis through multiple mechanisms. This lipid profile results from insulin resistance effects on hepatic lipoprotein metabolism and peripheral lipolysis.

Insulin resistance impairs the ability of insulin to suppress hepatic very low density lipoprotein production while also reducing lipoprotein lipase mediated clearance of triglyceride rich lipoproteins . The resulting hypertriglyceridemia promotes cholesterol ester transfer protein mediated exchange of triglycerides from very low density lipoprotein to high-density lipoprotein and low-density lipoprotein, generating triglyceride enriched particles that become substrates for hepatic lipase. This process produces small dense low-density lipoprotein particles that have enhanced atherogenic potential due to increased arterial wall penetration, reduced receptor mediated clearance, and greater susceptibility to oxidative modification .

Oxidized low-density lipoprotein plays a central role in atherosclerosis initiation and progression. These modified lipoproteins are readily taken up by macrophages through scavenger receptors unregulated by negative feedback, leading to foam cell formation. Oxidized low-density lipoprotein also stimulates endothelial adhesion molecule expression, promotes inflammatory cytokine production, and induces vascular smooth muscle cell migration and proliferation. The oxidative modification process is enhanced in metabolic syndrome due to increased oxidative stress and reduced antioxidant capacity.

Inflammatory Pathways and Immune Activation - Chronic low-grade inflammation represents a unifying feature of metabolic syndrome and a key driver of atherosclerosis. The inflammatory state in metabolic syndrome originates from multiple sources including adipose tissue macrophages, hepatic inflammation, and immune cell activation. C-reactive protein, a marker of systemic inflammation, is typically elevated in metabolic syndrome and independently predicts cardiovascular events .The c-Jun N-terminal kinase pathway has emerged as a critical molecular link between metabolic stress and inflammatory signaling. Obesity and nutrient excess activate c-Jun N-terminal kinase in metabolic tissues, leading to serine phosphorylation of insulin receptor substrate one which inhibits normal insulin signaling . This same pathway in vascular cells promotes inflammatory gene expression and contributes to atherosclerosis. Mice deficient in c-Jun N-terminal kinase show protection from obesity induced insulin resistance and atherosclerosis, highlighting the importance of this pathway. The endoplasmic reticulum stress response represents another mechanism linking metabolic dysfunction to inflammation and atherosclerosis. Nutrient excess and lipid accumulation in metabolic syndrome create endoplasmic reticulum stress in multiple cell types, activating the unfolded protein response. This response, while initially adaptive to restore protein folding homeostasis, can trigger

inflammatory signaling and cell death when sustained . Endoplasmic reticulum stress in macrophages promotes lipid accumulation and inflammatory cytokine production, while in endothelial cells it impairs nitric oxide production and increases adhesion molecule expression.

Oxidative Stress and Endothelial Dysfunction

Oxidative stress, defined as an imbalance between reactive oxygen species production and antioxidant defense mechanisms, characterizes metabolic syndrome and directly contributes to endothelial dysfunction and atherosclerosis. Multiple metabolic disturbances in the syndrome converge to increase reactive oxygen species generation.Hyperglycemia promotes oxidative stress through multiple pathways including glucose auto-oxidation, advanced glycation end product formation, and activation of protein kinase C. Elevated free fatty acids increase mitochondrial reactive oxygen species production and activate NADPH oxidase. Adipose tissue derived inflammatory cytokines further stimulate oxidative stress in vascular cells . The resulting oxidative environment has numerous pro-atherogenic effects. Nitric oxide bioavailability becomes critically impaired in oxidative stress conditions. Superoxide rapidly reacts with nitric oxide, forming peroxynitrite and reducing the availability of this protective molecule. Peroxynitrite itself can nitrate proteins, further compromising vascular function. Reduced nitric oxide bioavailability impairs endothelium dependent vasodilation, promotes platelet aggregation, and enhances leukocyte adhesion. These functional changes represent early steps in atherogenesis and predict future cardiovascular events .

Clinical Evidence Linking Metabolic Syndrome to Atherosclerosis

Epidemiological Studies - Extensive epidemiological evidence supports the association between metabolic syndrome and atherosclerotic cardiovascular disease. The Framingham Heart Study demonstrated that metabolic syndrome predicts cardiovascular events independent of traditional risk factors, with hazard ratios ranging from one point five to two point zero depending on the population and outcome examined . This predictive value extends across diverse populations including European, Asian, and African cohorts.

Recent studies have extended these findings to younger populations. A large South Korean cohort study including over three point six million adults under forty years demonstrated that metabolic syndrome significantly increases risk for premature atherosclerotic cardiovascular disease . Individuals with persistent metabolic syndrome had approximately two fold increased risk for myocardial infarction or ischemic stroke compared to those without metabolic syndrome. Each component independently contributed to risk, with elevated blood pressure showing the strongest association.

The relationship between metabolic syndrome and subclinical atherosclerosis has been documented using multiple imaging modalities. Coronary artery calcium scoring, carotid intima media thickness, and brachial artery flow mediated dilation all demonstrate worse values in individuals with metabolic syndrome compared to those without, even in the absence of clinical cardiovascular disease . These findings indicate that metabolic syndrome promotes early, subclinical vascular damage that precedes clinical events.

Metabolic Syndrome Score and Atherosclerosis Progression - Traditional binary classification of metabolic syndrome as present or absent fails to capture the full spectrum of metabolic risk. Recent research has explored continuous metabolic syndrome scores that better reflect the graded relationship between metabolic abnormalities and vascular damage. One study demonstrated that metabolic syndrome score, calculated from the five components, shows stronger associations with arterial stiffness and endothelial dysfunction than the binary diagnosis .

Each standard deviation increase in metabolic syndrome score was associated with significant changes in vascular measures, including increased brachial ankle pulse wave velocity reflecting arterial stiffness and decreased brachial flow mediated dilation reflecting endothelial function . These associations remained significant after adjustment for potential confounders and were stronger than associations with individual components. The metabolic syndrome score also correlated with inflammatory markers including leukocyte count and high sensitivity C reactive protein, suggesting that the inflammatory burden increases progressively with worsening metabolic status.

Metabolomic Profiling and Atherosclerosis Risk - Advances in metabolomic technologies have enabled detailed characterization of metabolic disturbances associated with atherosclerosis risk. Comprehensive plasma metabolomic analysis reveals distinct metabolic states that correlate with atherosclerotic burden beyond traditional risk factor assessment. Studies integrating metabolomics with clinical data identify specific metabolites and pathways associated with atherosclerosis independent of conventional metabolic syndrome components . Metabolites involved in amino acid metabolism, particularly phenylalanine and tyrosine catabolism, show strong associations with atherosclerosis. Gamma glutamyl glutamic acid and homovanillic acid sulfate have been identified as metabolites associated with atherogenic state regardless of the specific clinical condition . These metabolomic signatures may reflect underlying metabolic disturbances not captured by routine clinical measurements and could potentially improve risk stratification.

Therapeutic Implications and Intervention Strategies

Lifestyle Modification lifestyle interventions remain the cornerstone of metabolic syndrome management and atherosclerosis prevention. Weight loss through caloric restriction and increased physical activity addresses the root causes of metabolic dysfunction. Modest weight loss of five to ten percent improves all metabolic syndrome components, reducing insulin resistance, improving lipid profiles, lowering blood pressure, and decreasing inflammatory markers . Dietary composition significantly influences metabolic health independent of caloric intake. Diets rich in fruits, vegetables, whole grains, and healthy fats while limiting refined carbohydrates, added sugars, and saturated fats demonstrate benefits for metabolic syndrome. The Mediterranean diet, in particular, has shown efficacy in reducing metabolic syndrome prevalence and cardiovascular events in randomized trials . Physical activity recommendations include at least one hundred fifty minutes per week of moderate intensity aerobic activity plus resistance training, which provides additional metabolic benefits.

Pharmacological Interventions Pharmacological treatment targets individual metabolic syndrome components based on established guidelines for blood pressure, lipid, and glucose management. Statin therapy reduces cardiovascular events in metabolic syndrome patients, with benefits proportional to baseline risk. More recently, proprotein convertase subtilisin kexin type nine inhibitors have shown efficacy in metabolic syndrome patients, significantly reducing low density lipoprotein cholesterol and cardiovascular events in those with established atherosclerotic disease . Analysis of the FOURIER trial demonstrated that evolocumab, a proprotein convertase subtilisin kexin type nine inhibitor, reduced low density lipoprotein cholesterol by approximately fifty eight percent in metabolic syndrome patients and decreased cardiovascular events with hazard ratio zero point eight three compared to placebo . Importantly, these benefits occurred without increased risk of new onset diabetes or worsening glycemic control, addressing concerns about potential adverse metabolic effects of intensive lipid lowering. Glucagon like peptide one receptor agonists and sodium glucose cotransporter two inhibitors have emerged as particularly valuable agents for metabolic syndrome patients with diabetes,

offering benefits beyond glucose control. These medications promote weight loss, improve blood pressure, and reduce cardiovascular events in high risk populations . Their mechanisms of action address multiple aspects of metabolic dysfunction simultaneously.

DISCUSSION

The evidence synthesized in this review establishes metabolic syndrome as a critical contributor to atherosclerosis development through interconnected mechanisms that create a profoundly pro-atherogenic environment. Understanding these mechanisms has important implications for clinical practice, research priorities, and public health policy.

Integration of Mechanisms - The various pathways linking metabolic syndrome to atherosclerosis do not operate in isolation but form an integrated network of mutually reinforcing abnormalities. Insulin resistance promotes dyslipidemia by altering hepatic lipoprotein metabolism and adipose tissue lipolysis. The resulting lipid abnormalities, particularly elevated free fatty acids, further impair insulin signaling and directly damage endothelial cells. Adipose tissue dysfunction generates inflammatory mediators that exacerbate insulin resistance and promote vascular inflammation. Oxidative stress arising from multiple sources impairs endothelial function and modifies lipoproteins, enhancing their atherogenicity .

This integration explains why metabolic syndrome confers cardiovascular risk beyond the sum of its components and why interventions targeting single abnormalities may have limited efficacy. The syndromic nature of the condition suggests that optimal management requires approaches addressing shared underlying mechanisms rather than individual components in isolation. This concept supports the investigation of therapies that target fundamental processes such as inflammation, oxidative stress, or insulin resistance.

Clinical Implications - The recognition that metabolic syndrome promotes atherosclerosis even in young individuals has important implications for cardiovascular risk assessment and prevention. Traditional risk stratification approaches focusing on ten year risk may underestimate lifetime risk in young adults with metabolic syndrome, potentially delaying preventive interventions until irreversible vascular damage has occurred . This suggests value in assessing long term or lifetime risk and considering metabolic syndrome status in clinical decision making. The continuous relationship between metabolic dysfunction and atherosclerosis, demonstrated by metabolic syndrome score studies, argues against simple dichotomous approaches to risk classification. Graded risk across the spectrum of metabolic abnormalities suggests that interventions should target metabolic health improvement rather than simply achieving binary diagnostic thresholds. This perspective supports population based approaches to shifting the entire distribution of metabolic risk factors toward healthier levels.

The strong association between cumulative metabolic risk exposure and cardiovascular outcomes highlights the importance of early and sustained intervention. Metabolic syndrome identified in young adulthood predicts cardiovascular events decades later, suggesting that the duration of exposure to metabolic abnormalities matters for atherosclerosis development . This finding supports public health strategies targeting metabolic health in children and young adults to prevent the lifetime accumulation of risk.

Controversies and Unresolved Questions - Despite extensive research, several controversies regarding metabolic syndrome and atherosclerosis remain unresolved. Debate continues regarding whether metabolic syndrome represents a distinct pathophysiological entity or simply the co-occurrence of independently important risk factors. While the clustering of metabolic abnormalities is well established, whether this clustering reflects a shared underlying

mechanism or results from multiple independent processes remains debated . The optimal diagnostic criteria for metabolic syndrome across diverse populations remain uncertain, particularly regarding waist circumference thresholds. Ethnic differences in body composition and metabolic risk suggest that universal cutoffs may not be appropriate, but the evidence base for population specific thresholds varies considerably across groups . This uncertainty complicates clinical practice and epidemiological comparisons. Whether treating metabolic syndrome as a unified condition improves outcomes compared to treating individual components has not been definitively established. While the syndromic concept has heuristic value and may promote comprehensive risk factor management, randomized trials directly comparing these approaches are lacking. The absence of medications specifically approved for metabolic syndrome as a condition reflects this uncertainty.

Future Research Directions - Several priority areas for future research emerge from this review. Elucidation of the molecular mechanisms linking specific metabolic disturbances to vascular pathology could identify novel therapeutic targets. The role of emerging factors such as gut microbiota composition, circadian disruption, and environmental exposures in metabolic syndrome associated atherosclerosis warrants investigation. Longitudinal studies examining the relationship between metabolic syndrome trajectories and atherosclerosis progression could inform optimal timing and intensity of interventions. Understanding whether reversal of metabolic syndrome reverses or stabilizes atherosclerotic changes has important clinical implications. Studies of intensive lifestyle and pharmacological interventions in young adults with metabolic syndrome could determine whether early intervention prevents or delays atherosclerosis development. Development and validation of improved risk stratification tools incorporating metabolic syndrome status, duration, and severity could enhance clinical decision making. Integration of metabolomic, proteomic, and genetic information with traditional risk factors may enable personalized approaches to prevention and treatment. Comparative effectiveness research examining different treatment strategies in metabolic syndrome patients could guide evidence based practice.

RESULTS

The comprehensive review of current literature reveals several key findings regarding the role of metabolic syndrome in atherosclerosis development. Epidemiological studies consistently demonstrate that metabolic syndrome significantly increases cardiovascular disease risk, with affected individuals having approximately two fold higher risk for cardiovascular events compared to those without the syndrome. This elevated risk extends across diverse populations and age groups, including young adults under forty years . The prevalence of metabolic syndrome has reached epidemic proportions globally, affecting approximately twenty five percent of the world adult population. In the United States, prevalence approaches forty percent, with even higher rates among older adults and certain ethnic groups . Developing countries show rapidly increasing prevalence associated with adoption of Western dietary patterns and sedentary lifestyles, creating a growing global health challenge.

Molecular investigations have elucidated multiple interconnected mechanisms linking metabolic syndrome to atherosclerosis. Insulin resistance causes selective impairment of protective endothelial insulin signaling while preserving pro-atherogenic pathways, creating vascular dysfunction. Adipose tissue dysfunction in obesity leads to altered adipokine secretion with reduced protective adiponectin and increased inflammatory mediators. Dyslipidemia characterized by elevated triglycerides, reduced high-density lipoprotein, and small dense low-density lipoprotein particles promotes lipoprotein modification and foam cell formation. Chronic inflammation mediated through pathways including c-Jun N-terminal kinase activation and

endoplasmic reticulum stress creates a vascular environment conducive to atherosclerosis. Oxidative stress from multiple sources impairs endothelial function and enhances lipoprotein atherogenicity . Clinical studies demonstrate that metabolic syndrome promotes both subclinical and clinical atherosclerosis. Individuals with metabolic syndrome show increased coronary artery calcium, greater carotid intima media thickness, and impaired endothelial function compared to those without the syndrome . The relationship between metabolic dysfunction and vascular damage appears continuous, with metabolic syndrome scores showing stronger associations with atherosclerosis than binary diagnosis . Metabolomic profiling reveals distinct metabolic signatures associated with atherosclerosis risk beyond traditional risk factors. Specific metabolites and pathways, including amino acid metabolism disturbances, characterize individuals with increased atherosclerotic burden . These findings suggest potential for improved risk stratification through metabolomic assessment.

Therapeutic interventions targeting metabolic syndrome components demonstrate efficacy in reducing atherosclerosis risk. Lifestyle modification addressing diet and physical activity improves all metabolic syndrome components and reduces cardiovascular events. Pharmacological treatments including statins, proprotein convertase subtilisin kexin type nine inhibitors, and newer diabetes medications with cardiovascular benefits provide additional risk reduction . Early intervention appears particularly important, as cumulative exposure to metabolic abnormalities over time increases cardiovascular risk .

CONCLUSION

Metabolic syndrome plays a fundamental and multifaceted role in the development and progression of atherosclerosis through integrated mechanisms that create a profoundly pro-atherogenic environment. The syndrome, characterized by central obesity, insulin resistance, dyslipidemia, and hypertension, affects approximately one quarter of the global adult population with even higher prevalence in developed nations. The substantial and increasing burden of metabolic syndrome worldwide represents a major public health challenge requiring urgent attention. The pathophysiological links between metabolic syndrome and atherosclerosis involve complex interactions among multiple systems. Insulin resistance disrupts normal vascular homeostasis while promoting dyslipidemia. Adipose tissue dysfunction generates inflammatory mediators and alters protective adipokine profiles. Dyslipidemia produces highly atherogenic lipoprotein particles susceptible to oxidative modification. Chronic inflammation and oxidative stress create a vascular environment conducive to endothelial dysfunction, plaque formation, and eventual clinical events. These mechanisms do not operate independently but form an integrated network where each abnormality reinforces the others, explaining the amplified cardiovascular risk associated with the syndrome. Clinical evidence robustly demonstrates that metabolic syndrome increases risk for both subclinical atherosclerosis and clinical cardiovascular events. This relationship holds across diverse populations and age groups, with even young adults showing significantly elevated risk. The continuous nature of the association between metabolic dysfunction and vascular damage suggests that metabolic health exists on a spectrum and that interventions improving metabolic status at any level confer cardiovascular benefit.

Effective management of metabolic syndrome for atherosclerosis prevention requires comprehensive approaches addressing both individual components and shared underlying mechanisms. Lifestyle modification remains foundational, with weight loss, dietary improvement, and increased physical activity improving all aspects of metabolic health. Pharmacological interventions targeting specific components provide additional benefit, with newer agents offering pleiotropic effects beyond their primary indications. Early intervention is crucial, as cumulative exposure to metabolic abnormalities over time increases cardiovascular

risk. Future efforts should focus on several priorities. Improved understanding of molecular mechanisms may identify novel therapeutic targets. Enhanced risk stratification incorporating metabolic syndrome severity, duration, and metabolomic profiles could enable personalized prevention strategies. Public health initiatives addressing the root causes of the metabolic syndrome epidemic through environmental and policy changes are essential for population level impact. Clinical guidelines should provide clearer recommendations for cardiovascular risk assessment and management in young adults with metabolic syndrome. In conclusion, metabolic syndrome represents a critical determinant of atherosclerosis risk through interconnected mechanisms that create a profoundly pro-atherogenic environment. Addressing this syndrome through integrated clinical and public health approaches offers substantial potential for reducing the global burden of atherosclerotic cardiovascular disease.

REFERENCES

1. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Frontiers in Nutrition. 2025;12:1661603.

2. Association between Metabolic Syndrome Score and Subclinical Atherosclerosis. Reviews in Cardiovascular Medicine. 2025;26(3):26811.

3. Molecular Mechanisms of Metabolic Syndrome. BADERC Research Profile. 2025.

4. Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. Journal of Carcinogenesis. 2025;24(3S):441-448.

5. The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases. Hormone and Metabolic Research. 2024;56(10):683-696.

6. Stratification of Atherosclerosis based on Plasma Metabolic States. Journal of Clinical Endocrinology and Metabolism. 2024;109(5):1250-1262.

7. Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome. Diabetology and Metabolic Syndrome. 2025;17:245.

8. Evolocumab Reduces CV Events, LDL-C in Patients with Metabolic Syndrome on Statins. HCPLive. 2020.

9. Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions. International Journal of Molecular Sciences. 2025;26(8):3562.

10. Metabolic syndrome and premature atherosclerotic cardiovascular disease: insights for the individual and the population. European Journal of Preventive Cardiology. 2024;31(10):1189-1192.